# Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)

> **NCT02553642** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 81 (actual)

## Conditions studied

- Bladder Cancer
- Melanoma

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Nivolumab plus Ipilimumab

## Key facts

- **NCT ID:** NCT02553642
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-14
- **Primary completion:** 2024-04-29
- **Final completion:** 2024-04-29
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2025-07-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02553642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02553642, "Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02553642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*